Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments
AbstractAssessing programmed death ligand 1 (PD-L1) expression on tumor cells (TCs) using Food and Drug Administration-approved, validated immunoassays can guide the use of immune checkpoint inhibitor (ICI) therapy in cancer treatment. However, substantial interobserver variability has been reported using these immunoassays. Artificial intelligence (AI) has the potential to accurately measure biomarker expression in tissue samples, but its reliability and comparability to standard manual scoring remain to be evaluated. This multinational study sought to compare the %TC scoring of PD-L1 expression in advanced urothelial car...
Source: Virchows Archiv - April 4, 2024 Category: Pathology Source Type: research

Programmatic considerations and evidence gaps for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: Stakeholder analysis
by Megan Auzenbergs, Clara Maure, Hyolim Kang, Andrew Clark, Oliver Brady, Sushant Sahastrabuddhe, Kaja Abbas Chikungunya can have longstanding effects on health and quality of life. Alongside the recent approval of the world ’s first chikungunya vaccine by the US Food and Drug Administration in November 2023 and with new chikungunya vaccines in the pipeline, it is important to understand the perspectives of stakeholders before vaccine rollout. Our study aim is to identify key programmatic considerations and gaps in Ev idence-to-Recommendation criteria for chikungunya vaccine introduction. We used purposive and snowball...
Source: PLoS Neglected Tropical Diseases - April 4, 2024 Category: Tropical Medicine Authors: Megan Auzenbergs Source Type: research

Profiling lecanemab as a treatment option for Alzheimer's disease
Expert Rev Neurother. 2024 Apr 3:1-9. doi: 10.1080/14737175.2024.2333970. Online ahead of print.ABSTRACTINTRODUCTION: In July 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. Considering the limited treatment options for AD, the approval of lecanemab offers hope and opens the door for other disease-modifying therapies in the pipeline.AREAS COVERED: In this review, the authors summarize the FDA treatment guidelines, other anti-amyloid agents, and drug information relevant to prescrib...
Source: Expert Review of Neurotherapeutics - April 3, 2024 Category: Neurology Authors: Emily R Schiller Bret David Silverglate George T Grossberg Source Type: research